Decline in rates of acquired multidrug-resistant tuberculosis after implementation of the directly observed therapy, short course (DOTS) and DOTS-Plus programmes in Taiwan
Open Access
- 10 April 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 68 (8) , 1910-1916
Abstract
To investigate the impact of the directly observed therapy, short course (DOTS) and DOTS-Plus strategies on changes in resistance profiles among Mycobacterium tuberculosis (MTB). We performed a retrospective analysis of resistance profiles among isolates of MTB obtained from 2160 consecutive patients with culture-confirmed pulmonary tuberculosis (TB) between 2005 and 2011 at a referral centre in southern Taiwan. Of the 2160 patients, 70 (3.2%) had primary multidrug-resistant (MDR)-TB, 178 (8.2%) had acquired MDR-TB, 10 (0.5%) had primary extensively drug-resistant (XDR)-TB, 23 (1.1%) had acquired XDR-TB and 5 (0.2%) had totally drug-resistant (TDR)-TB. Trend analysis revealed that the rates of acquired MDR-TB were significantly lower after implementation of the DOTS and DOTS-Plus programmes (P < 0.01). There was a significant negative correlation between the coverage rates of the DOTS and DOTS-Plus programmes and the rates of acquired MDR-TB (r = −0.84, P = 0.02 and r = −0.92, P = 0.03, respectively). The rates of resistance to rifampicin, isoniazid, ofloxacin, moxifloxacin, levofloxacin and para-aminosalicylic acid also decreased significantly during the study period. However, the rates of primary MDR-TB remained stable (P = 0.11). Multivariate logistic regression analysis showed that age ranging from 45 to 64 years, positive acid-fast stain results at the initiation of treatment and treatment without DOTS were independent risk factors associated with acquired MDR-TB. In addition, previous treatment for TB (100% versus 19% for TDR-TB and non-TDR-TB, P < 0.01) and treatment without DOTS (80% versus 44% for TDR-TB and non-TDR-TB, P = 0.18) were risk factors for TDR-TB. DOTS and DOTS-Plus are both effective at preventing the acquisition of MDR-TB in Taiwan.Keywords
This publication has 16 references indexed in Scilit:
- Acquired resistance to second-line drugs among persons with tuberculosis in the United States.Clinical Infectious Diseases, 2012
- Development of Extensively Drug-resistant Tuberculosis during Multidrug-resistant Tuberculosis TreatmentAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Drug Resistance Pattern of Mycobacterium Tuberculosis Complex at a Medical Center in Central Taiwan, 2003–2007Journal of Microbiology, Immunology and Infection, 2010
- Declining drug resistance of Mycobacterium tuberculosis isolates from elderly patients in Taiwan, 2000–2008European Journal of Clinical Microbiology & Infectious Diseases, 2010
- Clinical and genotypic characteristics of extensively drug-resistant and multidrug-resistant tuberculosisEuropean Journal of Clinical Microbiology & Infectious Diseases, 2010
- Emergence of New Forms of Totally Drug-Resistant Tuberculosis BacilliChest, 2009
- Extensively Drug‐ResistantMycobacterium tuberculosisduring a Trend of Decreasing Drug Resistance from 2000 through 2006 at a Medical Center in TaiwanClinical Infectious Diseases, 2008
- Comprehensive Treatment of Extensively Drug-Resistant TuberculosisNew England Journal of Medicine, 2008
- Extensively Drug-Resistant Tuberculosis,TaiwanEmerging Infectious Diseases, 2008
- Global Incidence of Multidrug‐Resistant TuberculosisThe Journal of Infectious Diseases, 2006